Post hoc analysis of a phase 3 trial (481 adults with MDD and inadequate antidepressant response): adjunctive lumateperone 42 mg vs placebo improved MADRS at day 43 with anxious distress (43%; LSMD −6.8, ES 0.85) and without (LSMD −3.5, ES 0.44).
Secondary analysisn = 481
Sachs et al. Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress: Post Hoc Analysis of a Phase 3, Randomized, Double-Blind Trial